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Abstract 
Epidermal growth factor receptor (EGFR) is a cell surface receptor that plays an 
essential role in cell proliferation and survival, and overexpression of EGFR is a common 
feature of human cancers. In Non-Small-Cell lung cancer (NSCLC), activating mutations of 
EGFR have also been described. We recently showed that mutant EGFR-L858R inhibits the 
expression of the p14ARF tumor suppressor protein to promote cell survival. In this study we 
defined the molecular bases by which EGFR controls Arf expression. Using various lung 
tumor models we showed that EGF stimulation inhibits Arf transcription by a mechanism 
involving the nuclear transport and recruitment of EGFR to the Arf promoter. We unraveled 
the vesicular trafficking protein Vps34 as a mediator of EGFR nuclear trafficking, and 
showed that its neutralization prevents the accumulation of EGFR to the Arf promoter in 
response to ligand activation. Finally in lung tumor cells that carry mutant EGFR-L858R, we 
demonstrated that inhibition of Vps34 using siRNA restrains nuclear EGFR location and 
restores Arf expression leading to apoptosis. These findings identify the Arf tumor suppressor 
as a new transcriptional target of nuclear EGFR and highlight Vps34 as an important regulator 
of the nuclear EGFR/Arf survival pathway. As a whole they provide a mechanistic 
explanation to the inverse correlation between nuclear expression of EGFR and overall 
survival in NSCLC patients.  
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Introduction 
Epidermal growth factor receptor (EGFR) belongs to a large family of membrane-
bound receptor tyrosine kinases that serve as mediators of cell signalling by extra-cellular 
growth factors, and play a pivotal role in physiological cell proliferation and behaviour. 
Increased levels of EGFR gene expression are observed in many cancers and frequently 
associated with an adverse prognosis (1, 2). In addition, in lung cancer, oncogenic mutations 
inside the tyrosine kinase domain of EGFR have been reported to confer tumor cell 
dependence on EGFR-mediated pro-survival signalling, and high susceptibility to apoptosis 
induced by EGFR tyrosine kinase inhibitors (EGFR-TKI, Gefitinib)(3-5). Binding of growth 
factor such as EGF induces EGFR homo- or heterodimerization and autophosphorylation of 
the intracellular domain. This promotes the recruitment of adaptator molecules which trigger 
the activation of signal transduction pathways including the RAS/MAPK, the 
phosphoinositide-3-kinase (PI3K)/AKT and the signal transducer and activator of 
transcription (STAT) pathways (6-10). These downstream signaling activities regulate 
proliferation, survival, mobility and differentiation in many different cell types. Results of 
several recent studies show that receptor tyrosine kinase such as EGFR can also transmit 
signal from sub-cellular localisations other than their classical plasma membrane location, 
including the nucleus (11-13). Hence, nuclear EGFR has been shown to regulate a variety of 
cellular functions such as cell proliferation, DNA replication and repair, and signal 
transduction both in normal tissues and in human diseases including cancer (14) (15-17). The 
nuclear presence of EGFR is emerging as an important marker in many human cancer (13, 
18), and some mechanisms underlying nuclear EGFR-mediated tumor progression have been 
described. As an example in nasopharyngeal carcinoma induced by Epstein-Barr virus, the 
EBV-encoded latent membrane protein 1 (LMP1) was found to enhance transactivation of 
cyclin D1 and cyclin E by nuclear EGFR thereby fostering cell proliferation (19). In lung 
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cancer, the nuclear presence of EGFR was recently associated with poor clinical prognosis 
(18). However, the molecular mechanisms by which a nuclear signalisation of EGFR may 
contribute to lung cancer progression are not understood. 
Arf tumor suppressor (p14ARF in humans, p19ARF in mice) is encoded by the 
Ink4a/Arf locus which also houses the cyclin-dependent kinase inhibitor p16INK4a. Due to 
splicing events, separate promoters, and unique first exons, the two proteins share no 
homology and have distinct functions (20, 21). P14ARF is a key activator of the p53 pathway 
but also displays inhibitory cell growth properties independently of p53 (22, 23). 
Furthermore, p14ARF is involved in the maintenance of genomic stability in response to 
DNA damage and oncogenic stress, and its expression is a major break to cancer development 
including lung cancer (24). We recently identified a cross talk between EGFR and Arf 
signaling pathways in lung tumor cells, and showed that activated EGFR inhibits the 
expression of the p14ARF protein (25). Here, we decipher the molecular mechanisms by 
which EGFR represses p14ARF expression. We demonstrate that EGFR inhibits Arf 
transcription by a mechanism involving its nuclear translocation and accumulation to the Arf 
promoter. We also show that the Class III PI3K Vps34 facilitates nuclear trafficking and 
recruitment of EGFR to the Arf promoter, and demonstrate that this Vps34/nuclear EGFR 
network counteracts Arf expression and pro-apoptotic signaling in lung tumor cells expressing 
mutant EGFR. These results provide the first evidence that a Vps34/nuclear EGFR trafficking 
contributes to the survival of lung tumor cells through inhibition of the Arf tumor suppressor. 
 
Results 
 
EGFR decreases Arf transcript level 
 
 We previously reported a decreased expression of the p14ARF protein by activated 
EGFR in H1719 (ligand stimulated WT EGFR) and H1975 (mutant EGFR-L858R) cells (25). 
Here, we investigated the molecular mechanisms involved. To answer, we first neutralized 
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EGFR expression using specific small interfering RNA (siRNA) and studied Arf expression 
by western blot and RT/qPCR analyses in both cell lines. Consistent with our previous data 
(25), the expression level of the p14ARF protein was increased in EGFR depleted cells 
(Figure 1A bottom). Interestingly, we observed that the accumulation of the p14ARF protein 
correlated with a significant upregulation of its transcript expression level in both cellular 
models (Figure 1A top). Same results were obtained in the HCC827 cell line which express 
the active mutant EGFR-Del19, ensuring against potential cell type-specific effects. To 
confirm the negative effect of EGFR on Arf transcripts, cells were serum starved for 24 hours 
and Arf expression was studied after EGF stimulation. In all cellular models, the 
downregulation of the p14ARF protein was associated with a significant diminution of its 
transcripts (Figure 1B and supplementary Fig1). Same results were obtained when H1719 
cells were treated with Amphiregulin (Areg), another natural ligand for EGFR (Figure 1C). 
Importantly, expression of the INK4a transcript as well as the p16INK4a protein, which are 
also encoded by the INK4a-Arf locus, was not affected by ligand stimulation or when EGFR 
was neutralized using specific siRNA in all three cell lines (Figure 1D and supplementary 
Figure 2). Taken together, these data demonstrated that wild type and mutant EGFRs 
specifically downregulate Arf transcript level. Of note we observed that EGF does not 
decrease the stability of Arf mRNAs (supplementary Figure 3), suggesting a role of EGFR in 
a negative control of Arf transcription. 
 
Nuclear EGFR signalling pathway inhibits Arf transcription  
Recent evidences indicate that RTKs such as EGFR act as transcriptional regulators 
when they are translocated to the nucleus (14, 26). Therefore, to investigate whether nuclear 
EGFR might control Arf transcription, we first checked whether EGFR accumulates in the 
nucleus of our cellular models in response to EGF stimulation. As shown by western blotting 
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following subcellular fractionation, we found that EGF ligand increased nuclear EGFR 
expression in all three lung cancer cell lines (Figure 2A). These results were also supported by 
examination of EGFR by fluorescence pseudo-confocal (apotome) microscopy showing 
enrichment of a nuclear punctuated EGFR signal after EGF stimulation using three different 
antibodies (Figure 2B and Supplementary Figure 4). To go further, we used siRNA against 
importin β1 or Brefeldin A (BFA) treatment to block nuclear trafficking of EGFR. In both 
context, inhibiting the EGFR transport to the nucleus prevented the downregulation of both 
the mRNA and the p14ARF protein upon EGF stimulation (Supplementary Figure 5). As 
siRNA against importin β1 and BFA do not target specifically EGFR trafficking, we took 
advantage of CHO cells stably expressing wild type EGFR or an EGFR-pNLS mutant in 
which the nuclear localization signal (NLS) of EGFR is mutated (27). In agreement with the 
inhibition of Arf by EGFR, EGF stimulation decreased expression of both Arf transcript and 
protein in CHO-EGFR cells (data not shown). More importantly, we observed that the 
expression level of both Arf mRNA and protein was significantly increased in CHO-EGFR-
pNLS which do not express nuclear EGFR, compared to CHO-EGFR cells in which EGFR 
was present in the nucleus (Figure 2C and D). In agreement with our previous results, 
expression of INK4a did not vary significantly in CHO-EGFR-pNLS cells (Supplementary 
Figure 2E and F). As a whole, these data indicated nuclear EGFR is important for the 
repression of Arf expression. 
As a transcription factor, the nuclear EGFR complex is known to target AT-rich 
minimal consensus sequences (28). Very interestingly, « in silico » analysis of the Arf 
promoter highlighted several ATRSs as putative EGFR-targeting sequences. Therefore, we 
used in vivo ChIP-qPCR assays to study whether nuclear EGFR is recruited to the Arf 
promoter. HCC827 cells were first used in this setting as they express high levels of nuclear 
EGFR (Figure 2A). Nuclear EGFR was precipitated from cells stimulated or not with EGF, 
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and qPCR was performed using primers surrounding the 3 most proximal putative ATRSs 
within the Arf promoter. We showed that nuclear EGFR accumulates on the Arf promoter in 
response to ligand stimulation (Figure 2E). In contrast, binding was not detected when 
chromatin immunoprecipitation was performed with control IgG and/or when irrelevant 
primers (Neg) were used for the qPCR, ensuring the specificity of the ChIP results. Same data 
were obtained in the H1975 model (Supplementary Figure 6). Altogether, these results 
demonstrated that nuclear EGFR is recruited to the Arf promoter in response to EGF 
stimulation in both EGFR mutant cell lines and inhibits Arf transcription. Unfortunately and 
despite several attemps, we could not obtain reliable ChIP results in H1719 cells. This could 
be due to the low level of expression of endogenous nuclear EGFR in these cells compared to 
H1975 and HCC827 cells in which the EGFR gene is strongly amplified. 
 
PI3K but not AKT controls the nuclear translocation of EGFR  
Next, we wanted to characterize the molecular mechanisms controlling EGFR nuclear 
trafficking. Interestingly, we observed that pharmacological inhibition of EGFR prevents its 
nuclear accumulation following ligand activation and rescues the expression of both the Arf 
transcript and protein (Supplementary Figure 7). Therefore, we speculated that signal 
transduction pathways known to be downstream from the EGFR may promote its oncogenic 
nuclear translocation. In order to assess which pathways could be involved, we used specific 
pharmacological inhibitors. We found that pharmacological suppression of the RAS/MAPK 
or STATs pathways using U0126 and cucurbitacin respectively did not prevent the nuclear 
trafficking of EGFR in response to EGF nor the p14ARF downregulation (Supplementary 
Figure 8A and 8B). In contrast, the PI3K/AKT inhibitor wortmanin strongly inhibited EGFR 
nuclear transport in the same conditions whatever the EGFR status (WT or mutant) (Figure 
3A and 3B and data not shown). This was accompagnied by a diminished accumulation of 
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EGFR on the Arf promoter (Figure 3C) and more importantly by the rescue of Arf mRNA 
expression (Figure 3D). To go further, we investigated the role of AKT by using Triciribin, a 
specific AKT inhibitor. Surprisingly, inhibition of AKT did not prevent the nuclear 
translocation of EGFR (Figure 3B and 3E), nor the downregulation of Arf transcript (Figure 
3D). These results were confirmed with another specific AKT inhibitor, namely MK2206 
(Supplementary Figure 8C). Altogether, these data indicated that activation of a PI3K-
dependent AKT-independent pathway drives the nuclear translocation of EGFR and the 
inhibition of Arf transcription. 
 
Class III PI3K Vps 34 facilitates EGFR nuclear transport and binding to the Arf 
promoter 
 The family of PI3K enzymes comprises three different classes, I, II and III. 
Wortmamin and LY294002 are broad inhibitors against PI 3-kinases although members of the 
class II show decreased sensitivity. The class I PI3K is activated downstream of receptor 
tyrosine kinases such as EGFR and stimulates the AKT signaling pathway. In agreement with 
our previous results (Figure 3), treating cells with the selective class I PI3K inhibitor GDC-
0941 did not prevent EGFR nuclear transport in response to EGF, nor p14ARF 
downregulation (Supplementary Figure 9). Interestingly, previous work in yeast had 
implicated class III PI 3-kinase in diverse intracellular trafficking events including endosome-
to-Golgi retrograde transport (29). Therefore, we speculated that class III PI 3-kinase may 
play a role in the nuclear trafficking of EGFR in our cellular models. The Vacuolar sorting 
protein 34 (VPS34) is the single class III PI3K isoform in human. Because of the lack of 
specific pharmacological inhibitors of human Vps34, we used siRNA to disturb Vps34 
expression in the presence or absence of EGF stimulation. The results showed that 
neutralization of Vps34 expression in H1719 cells prevents the nuclear transport of EGFR 
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following EGF stimulation as visualized by western blotting following subcellular 
fractionation or by confocal microscopy (Figure 4A and 4B). Importantly, this was 
accompagnied by a partial but significant and reproducible rescue of Arf transcript (Figure 
4C) and the p14ARF protein was not decreased in Vps34 knock-down cells following EGF 
stimulation (Figure 4A). In addition, we observed that depriving cells from Vps34 using 
siRNA diminished the recruitment of EGFR to the Arf promoter following EGF treatment 
(Figure 4D), thereby indicating that Vps34 is important for the recruitment of nuclear EGFR 
to the Arf promoter. Altogether, these data strongly suggested that the Class III Vps34 
contributes to the nuclear trafficking of EGFR in lung tumor cells. 
 
Inhibition of Vps34 prevents nuclear trafficking of mutant EGFR and restores p14ARF-
dependent apoptosis in lung adenocarcinoma cells 
 We previously reported that the EGFR-L858R mutant inhibits the expression of the 
p14ARF protein to promote cell survival, and showed that Arf knockdown reduces apoptosis 
caused by siEGFR  (25). As we demonstrated in this study that nuclear EGFR downregulates 
Arf transcript level, we speculated that nuclear translocation of the EGFR-L858R mutant 
might inhibit p14ARF-dependent apoptotic signaling pathway. To adress this issue we 
transfected H1975 cells with siRNA against Vps34. In these cells, we confirmed that 
neutralization of Vps34 decreases the nuclear expression level of EGFR (Figure 5A) and 
upregulates those of Arf transcript (Figure 5B). Our previous results demonstrated that 
p14ARF promotes apoptosis of H1975 cells by activating an original pSTAT3(705)-
dependent pro-apoptotic pathway that downregulates Bcl-2 (25). In Vps34 knocked-down 
cells, we showed that Arf upregulation was accompagnied by the accumulation of pSTAT3-
Y705, the downregulation of Bcl-2 expression and the induction of apoptosis (Figure 5A and 
C). Importantly, silencing Arf expression using siRNA rescued Vps34 knock-down cells from 
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all these modifications (Figure 5A) and diminished apoptosis occurrence (Figure 5C). We 
also noticed a slight increase of cell proliferation after 72h of siRNA transfection (data not 
shown). Of note, silencing of INK4a had no effect on apoptosis caused by Vps34 
downregulation (Supplementary Figure 10). Together, these results indicated that a Vps34-
dependent nuclear signalisation of mutant EGFR promotes the survival of lung 
adenocarcinoma cells by counteracting the pro-apoptotic function of the Arf tumor suppressor 
(Figure 5D).  
 
Discussion 
In recent years, a novel mode of EGFR signaling has emerged by which EGFR 
translocates to the nucleus after endocytosis where it displays unique functions. Nuclear 
accumulation of EGFR has been linked to various diseases including cancer and was 
associated with poor clinical outcome in that case (18, 30-32). However, a few studies have 
addressed the molecular determinants accounting for the nuclear trafficking and signaling 
pathways of EGFR in tumors. The present study identifies a mechanism by which nuclear 
EGFR might contribute to lung adenocarcinoma progression. We show that nuclear EGFR 
accumulates on the Arf promoter and inhibits Arf transcription. Moreover, we demonstrate 
that the vesicular trafficking protein Vps34 mediates the nuclear transport of EGFR to inhibit 
p14ARF-dependent apoptosis, thereby unravelling Vps34 as a new regulator of EGFR 
signaling. 
The well-characterized trafficking of cell surface EGFR is routed, via endocytosis and 
endosomal sorting, to the lysosomes for degradation or to the plasma membrane for recycling. 
In addition to the above well-characterized trafficking routes, alternative fate for endocytosed 
activated EGFR involves transport to different compartments within the cells, including the 
nucleus (11, 33, 34). Although nuclear detection of EGFR has been associated with tumor 
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agressiveness, the mechanisms underlying the nuclear accumulation of EGFR in cancer are 
not understood. In this study we identify the class III PI3K Vps34 as an important mediator of 
the nuclear translocation of EGFR as we showed that its neutralization prevents the 
translocation of both ligand-stimulated and mutant EGFR in the nucleus of lung tumor cells. 
Vps34 plays an important role in the control of vesicular protein sorting, a phenomenon that 
was fisrt discovered in yeast (35). In all eukaryotes, Vps34 has central functions in endosomal 
protein sorting, endosome-lysosome maturation, autophagy, and phagocytosis (36-38). Our 
results suggest that Vps34 might also facilitate the endosome-to-golgi sorting of RTK such as 
EGFR to allow nuclear transport. Previous studies have involved the AKT and PKC kinases 
in the aberrant accumulation of EGFR in the nucleus in response to therapy in breast and lung 
tumor cell lines respectively (15, 39). Our results show that these kinases do not control the 
nuclear translocation of EGFR in response to ligand stimulation (Figure 3 and data not 
shown). Collectively, these results support the fact that signalling pathways that mediate 
EGFR nuclear transport may vary according to the tumor type and/or the cellular stress.  
We demonstrated that nuclear EGFR inhibits the expression of Arf. As other members 
of the HER family which are expressed in our cellular models such as HER2, are subjected to 
nuclear trafficking(40), we cannot exclude the possibility that they could also negatively 
regulate Arf expression. We demonstrated that nuclear EGFR accumulates on the Arf 
promoter and inhibits the expression of Arf transcripts. It has been previously shown that, in 
the nucleus, EGFR functions as a co-transcription factor to enhance transcription of tumor 
promoting genes such as cyclin D1, iNOS, COX-2, Aurora A and c-Myc (27, 28, 41-43). In 
contrast, our results suggested for the first time that nuclear EGFR may also repress 
transcription of tumor suppressor genes to control tumor growth. Several transcription factors 
and complexes including Polycomb group (PcG) proteins have been reported to inhibit Arf 
transcription (44). Most important and well-characterized Arf repressors include the BMI-1 
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and Pokemon proteins which aberrant overexpression have been reported to contribute to lung 
carcinogenesis (45-48). Interestingly, previous studies reported that ligand-activated EGFR 
increases BMI-1 or Pokemon expression in head and neck and prostate cancer cells 
respectively (49, 50). We investigated the role of these proteins in the transcriptional 
inhibition of Arf by EGFR in our lung tumor models. However, the results showed that 
downregulation of Arf mRNA following EGFR activation was maintained when expression of 
either BMI-1 or Pokemon genes was neutralized using specific siRNA, indicating that they 
are probably not involved in that case (data not shown). Similar results were obtained when 
expression of other well-identified Arf repressors such as p53, E2F3b, Tbx2 and Tbx3 was 
knocked-down (data not shown). Therefore molecular mechanisms underlying transcriptional 
inhibition of Arf gene by nuclear EGFR require further investigation. 
Expression of p14ARF is decreased in many tumors including lung cancer, and 
previous studies have described a coupling between mutations of EGFR and downregulation 
of the p14ARF protein in NSCLC (51, 52). In agreement with an EGFR/Arf connection we 
recently demonstrated that EGFR inhibits the expression of the p14ARF protein to promote 
cell survival (25). In this study, we further deepened these results by providing the first 
evidence that a nuclear EGFR signaling pathway represses Arf transcription and pro-apoptotic 
function, and by identifying the Vps34 protein as an important mediator of this pathway. It 
was recently reported an inverse correlation between nuclear expression of EGFR and overall 
survival in NSCLC patients (18). Therefore, our data provide a mechanistic explanation to 
these in situ observations, and unravel the Vps34/nuclearEGFR/Arf network as a potential 
mechanism of lung cancer progression. Future studies are now required to validate the 
Vps34/nuclear EGFR connection as an oncogenic pathway in human tumor samples, 
especially as Vps34 inhibitors have been recently developped (53). Moreover, as nuclear 
accumulation of wild type EGFR was also ascribed to resistance to anti-EGFR monoclonal 
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antibody therapy (Cetuximab) in lung cancer models (54), it is tempting to speculate that 
aberrant trafficking of mutant EGFR in the nucleus may also contribute to the resistance of 
lung adenocarcinoma patients to EGFR-TKI treatment. 
 
Materials and Methods 
Cell culture and treatments 
HCC1719, HCC827 and H1975 cell lines (quindly provided by Pr A. Gazdar) were derived 
from human lung adenocarcinoma. HCC1719 cells carry a wild type EGFR, whereas HCC827 
harbour a LREA deletion in the exon 19 of EGFR and H1975 a missense substitution L858R 
in exon 21 of EGFR. All cells were maintained in RPMI-1640 + GlutaMAX medium 
(GIBCO, Cergy Pontoise, France) supplemented with 10% foetal calf serum in a humidified 
incubator with 5% CO2 at 37°C. CHO-EGFR and CHO-EGFR-pNLS were kindly provided 
by Dr Mien Chie Hung. They were cultured in DMEM-F12 medium (GIBCO, Cergy 
Pontoise, France) supplemented with 10% fetal calf serum. All cell lines were mycoplasma 
free. For growth factor stimulation, cells were incubated in serum-free medium for 24 hours 
and after medium change Rh-EGF (Eurobio, Courtaboeuf, France) (50ng/mL in HCC1719 
cells and 100ng/mL in HCC827 and H1975 cells) or rh-Amphiregulin (R&D SYSTEMS 
EUROPE, Lille, France) (50ng/ml) was added for 15 min or 24 hours. Pharmacological 
inhibitors were added 30 min prior EGF stimulation. Actinomycin D and Brefeldin A were 
purchased from Sigma-Aldrich (Saint Quentin Fallavier, France), Triciribin from Calbiochem 
(VWR, Fontenay-sous-bois, France), Gefitinib from AstraZeneca (Rueil-Malmaison, France), 
U0126 and LY294002 from Selleckchem (Souffelweyersheim, France), Cucurbitacin I and 
Wortmaninn from Santa Cruz (TEBU, Le Perray en Yvelines, France) and GDC0941 and 
MK2206 from Roche Diagnostics (Meylan, France). Apoptosis was studied on a total cell 
population using the PE-conjugated monoclonal active caspase 3 antibody apoptosis kit (BD 
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Biosciences, Pharmingen, Le Pont de Claix, France) according to the manufacturer’s protocol. 
Analysis was performed using a FACScan flow cytometer (BD Biosciences, Le Pont de 
Claix, France).  
 
Transfection of siRNA oligonucleotides 
The sequences designed to specifically target human EGFR, Importin β1, Vps34, INK4a and 
Arf RNAs were as follows: EGFR, 5’-CUCUGGAGGAAAAGAAAGU-3’; Importin β1, 5’-
GGACUUAUGUACAGCAUUU-3’; Vps34, 5’CCCAUGAGAUGUACUUGAACGUAAU-
3’, INK4a, 5’-CGCACCGAAUAGUUACGGU-3’ ; Arf, 5’-
GAACAUGGUGCGCAGGUUC-3’. For all interference experiments, the mismatch siRNA 
oligonucleotide used as a control was 5’-UCGGCUCUUACGCAUUCAA-3’. Cells were 
transfected with siRNA oligonucleotide duplexes using jetPrime reagent (OZYME, Saint 
Quentin en Yvelines, France) according to the manufacturer’s protocol. The cells were 
analysed 72H post-transfection. 
 
Cellular fractionation 
Cells were pelleted and washed twice with PBS 1X. Cells were resuspended in hypotonic 
buffer (10mM Tris-HCl pH 7.5, 10mM KCl, 1.5mM MgCl2, 0.5mM dithiothreitol, 0.02M 
NaF, 1mM Na3VO4, 1X EDTA free Protease Inhibitor Cocktail (Roche Diagnostics) for 20 
minutes on ice. Then, cells were centrifugated at 2000g for 5 minutes and pellets were 
resuspended in hypotonic buffer + 2% NP-40. Homogenates were incubated for 15 minutes 
on ice and centrifugated at 3000g during 15 minutes. The resulting supernatant formed the 
non-nuclear fraction. The nuclear pellets were washed four times with PBS 1X, resuspended 
in RIPA buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 0.5% Na deoxycholate, 1% NP-40, 
0.1% SDS, 0.02M NaF, 1mM Na3VO4, 1X EDTA free Protease Inhibitor Cocktail) and 
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sonicated. Homogenates were centrifugated at 13500g for 30 minutes, the resulting 
supernatant formed the nuclear fraction. Total proteins extracts was performed in RIPA buffer 
as described previously (25). Analysis of protein expression was performed by western 
blotting. EGFR, p14ARF and laminB intensities were quantified using the Image J software 
and the relative densitometric areas for EGFR or p14ARF were determined according to 
Lamin B signal  in each condition.  
 
Antibodies 
The anti-EGFR (D38B1), anti-p14ARF (4C6/4), anti-AKT, anti-pAKT (D9E), anti-ERK1/2 
(137F5), anti-pERK1/2 (D13.14.4E), anti-STAT3 (79D7), anti-pSTAT3 (D3A7), anti-Bcl-2, 
anti-cleaved caspase3 (Asp175) and anti-lamin B1 (D4Q4Z) antibodies were purchased from 
Cell Signaling (OZYME, Saint Quentin Yvelines, France). The anti-α tubulin (B-5-1-2), anti-
p16INK4a (sc-759) and the anti-importin β1 antibodies were purchased from Santa-Cruz 
(Clinisciences, Montrouge, France). The anti-Vps34 antibody was from Novusbio (R et D 
system Europe-Bio-Techne, Lille, France). 
 
RNA extraction, reverse transcription and real-time quantitative PCR analysis 
RNA was extracted using High Pure RNA isolation kit (Roche Diagnostics) according to the 
manufacturer’s protocol and subjected to Reverse Transcription using iScript RT supermix 
(Biorad, Marnes-la-Coquette, France). Quantitative PCR (qPCR) was performed with iTaq 
Universal SYBR Green Supermix (Biorad). The primers used for cDNA amplification were 
as follows: Arf S: 5’-GCGCAGGTTCTTGGTGAC-3’; Arf AS: 5’-
GGCTCCTCAGTAGCATCAGC-3’; INK4a S : 5’-GAGCAGCATGGAGCCTCC-3’ ; 
INK4a AS : 5’-GGCCTCCGACCGTAACTATT-3’ ; Vps34 S: 5’-
AAGCAGTGCCTGTAGGAGGA-3’; Vps34 AS: 5’-TGTCGATGAGCTTTGGTGAG-3’; 
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GAPDH S: 5’-CGAGATCCCTCCAAAATCAA-3’; GAPDH AS: 5’-
ATCCACAGTCTTCTGGGTGG-3’. Amplification of GAPDH was performed in all 
experiments and used as reference gene. Relative gene expression was calculated for each 
sample as the ratio of target cDNA copy number to GAPDH cDNA copy number. The data 
represent the mean +/- SD of at least three independent experiments.  
 
Chromatin Immunoprecipitation assay 
Cells were crosslinked with 1% formaldehyde for 10 minutes and subsequently processed 
using the ChIP-ITR Express kit (Active Motif, La Hulpe, Belgium) according to the 
manufacturer’s protocol. Immunoprecipitation was performed with either anti-EGFR antibody 
(Santa-Cruz) or rabbit IgG as a control at 4°C overnight. The immunoprecipitated complexes 
were purified using Chromatin IP DNA Purification kit (Active Motif) and subjected to 
QPCR using primers specific to the ARF promoter which were sense 5’-
GCGTGCAGCGGTTTAGTTTA-3’ and anti-sense 5’-CTCTATCCGCCAAT-CAGGAG-3’. 
Human Negative Control Primer Set 1 (Active Motif) was used as negative control. Input 
DNA sample corresponding to 1% of immunoprecipitated chromatin was analysed in parallel 
in order to normalized the results of each ChIP DNA sample to the corresponding input DNA 
sample. EGFR enrichment on ARF promoter was calculated after adjustment of normalized 
ChIP fraction for the normalized background (IgG). 
 
Indirect immunofluorescence 
For immunolocalisation studies, cells were fixed with 1% paraformaldehyde in PBS for 10 
min at room temperature, washed once with PBS, and permeabilised with 0.1% Triton X-100 
in PBS for 10 min. Blocking was performed for 45 min in 5% BSA. Incubation with anti-
EGFR antibody (D38B1) from Cell Signaling was carried out overnight at 4°C in a humid 
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chamber. Cells were then incubated for 45 min with Alexa 568 (Life Technologies, Saint 
Aubin, France), mounted in a solution containing 4,6-diamino-2-phenylindole (DAPI) (Roti 
®-Mount FluorCare DAPI, ROTH), vizualised by fluorescent microscopy using Axioimager 
microscope (Carl Zeiss, Jena, Germany) with the AxioVision® software at a 60x 
magnification and processed with Image J software. 
 
Statistical analysis 
All the data represent the mean ± s.d. of three independent experiments. All statistical 
analyses were performed using an unpaired Student’s t-test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001). P ≤ 0.05 was considered as statistically significant.  
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Figures legends 
 
Figure 1 EGFR downregulates Arf mRNA level 
A, Cells were transfected with control siRNA (Ctl) or siRNA against EGFR (siEGFR) for 72 
hours. Expression of Arf transcript was studied by quantitative PCR. qPCR data are 
represented as fold increase relative to non treated cells which were arbitrarily assigned to 1. 
Protein expression was analysed by western blot using indicated antibodies. Tubulin was used 
as a loading control. B, Cells were incubated with EGF (50ng/ml) for 24 hours. Expression of 
Arf was studied by qPCR and western blotting as described above. C, H1719 cells were 
treated with Amphiregulin (Areg) (50ng/ml) for 24 hours. Expression of Arf was studied by 
qPCR and western blotting as described above. D, H1719 cells were stimulated with EGF or 
Areg (50ng/ml) for 24 hours. Expression of INK4a was assessed by qPCR and western 
blotting. All the data represent the mean ± s.d. of three independent experiments. NS, not 
significant. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. Quantification of p14ARF protein levels 
was performed as described in the methods section and is numerically indicated below each 
lane. 
 
Figure 2 Nuclear EGFR inhibits Arf transcription 
A, B, Cells were stimulated for 15 min with EGF (50ng/ml). Western blotting was performed 
using indicated antibodies after subcellular fractionation. Levels of tubulin and lamin B were 
used as markers for cytosolic and nuclear fractions, respectively. Quantification of EGFR 
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protein levels is numerically indicated below each lane. Immunolocalisation of EGFR 
(D38B1, Red) was performed in H1719 cells using fluorescent pseudo-confocal (apotome) 
microscopy. DAPI (Blue) was used to counterstained nuclei . C, D, Expression of EGFR and 
Arf was studied by western blotting and/or qPCR in CHO cells constitutively expressing wild 
type (EGFR WT) or mutant EGFR (EGFRpNLS). Quantification of EGFR (Top line) and Arf 
(Bottom line) protein levels is numerically indicated below each lane. E, The 3 most proximal 
putative ATRS sites within the Arf promoter are illustrated. Arrows represent primers used in 
the chromatin immunoprecipitation (ChIP)/qPCR study. HCC827 cells were stimulated for 30 
min with EGF. The binding of EGFR to Arf promoter was analyzed by ChIP as described in 
the materials and methods section. IgG was used as a negative control for chromatin 
immunoprecipitation. qPCR with irrelevant primers (ChIP-ITR Express kit, Active Motif) was 
performed to ensure the specificity of the results. Data represent the mean ± s.d. of three 
independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. NS, not significant. 
 
Figure 3 PI3K but not AKT controls nuclear EGFR trafficking to inhibit Arf transcription 
H1719 cells were pre-treated for 30 min with Wortmanin (0.1µM) or Triciribin (10µM) 
before EGF stimulation for 15 min (A, B, C, E) or 24 hours (D). A, E, Western blotting was 
performed after sub-cellular fractionation using indicated antibodies. Quantification of EGFR 
protein levels is numerically indicated below each lane.  B, Expression of EGFR (D38B1, 
Red) was analysed by immunofluorescence and pseudo-confocal (apotome) microscopy. 
DAPI (blue) was used to counterstain nuclei. C, Chromatin immunoprecipitation was 
performed as previously described. D, Arf expression was analysed by qPCR as described. 
Data represent the mean ± s.d. of three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P 
≤ 0.001. NS, not significant.  
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Figure 4 Class III PI3K Vps34 controls nuclear trafficking and accumulation of EGFR to Arf 
promoter 
A,B,C, H1719 cells were transfected with control siRNA (Ctl) or siRNA against Vps34 
(siVps34) for 72h prior to EGF stimulation (50ng/ml) for an additional 15 min (A upper 
pannel, B) or for 48h prior to EGF stimulation (50ng/ml) for an additional 24 hours (A, lower 
pannel, C). EGFR and Vps34 expression was studied by western blotting after subcellular 
fractionation. Quantification of EGFR and Arf protein levels is numerically indicated below 
each lane. Immunolocalisation of EGFR (Red) was performed using fluorescent pseudo-
confocal (apotome) microscopy. DAPI (Blue) was used to counterstained nuclei  Expression 
of Arf transcript was studied by qPCR. D, HCC827 cells were transfected with control siRNA 
(Ctl) or siRNAs against Vps34 (siVps34) for 72h and stimulated with EGF (50ng/ml) for an 
additional 30 min. ChIP analysis was performed as previously described. All the data 
represent the mean ± s.d. of three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001.  
 
Figure 5 Nuclear trafficking of mutant EGFR by Vps34 inhibits p14ARF-dependent 
apoptosis in lung tumor cells 
A, B, C, H1975 cells were transfected with control siRNA (Ctl) or siRNAs against Vps34 
(siVps34) and/or Arf (siArf) for 72h. Western blotting was performed after subcellular 
fractionation. Neutralization efficiency of Vps34 expression was assessed by qPCR. 
Expression of Arf mRNAs was studied by qPCR as described above. Apoptosis was 
quantified by staining of active caspase3 followed by FACS analysis. Data represent the mean 
± s.d. of three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. D, A proposed 
model underlying the way by which the nuclear translocation of mutant EGFR through a 
Vps34-dependent mechanism negatively controls Arf expression to prevent cellular apoptosis.  
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